Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Ubicación

MS status

Recruitment Status

Fase

Drogas

Inmunoterapia previa permitida

NCT ID

Title key word search

Fecha en que se añadió el juicio

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Fase	Date Added	Ubicación	Prior IO Allowed	CRC-directed	Status	Drogas	Etiquetas
NCT ID NCT06455254	TitleCadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM	Fase Fase 2	Date Added 2024-06-12	Ubicación China	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas	Etiquetas MSS/ MMRp
NCT ID NCT06415851	TitleChemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab	Fase Fase 2	Date Added 2024-05-15	Ubicación China	Prior IO Allowed No	CRC-directed Sí	Status Aún no se ha contratado	Drogas	Etiquetas MSS/ MMRp
NCT ID NCT06412198	TitleA Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations	Fase Phase 1, Phase 2	Date Added 2024-05-14	Ubicación Massachusetts, United States Texas, United States	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas Adagrasib, cemiplimab, cetuximab	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06336902	TitleBotensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer	Fase Fase 1	Date Added 2024-03-29	Ubicación California, United States	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas Balstilimab, Botensilimab	Etiquetas MSS/ MMRp
NCT ID NCT06322693	TitleA Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)	Fase Fase 1	Date Added 2024-03-21	Ubicación Arizona, United States California, United States Colorado, United States Connecticut, United States District of Columbia, United States Florida, United States Georgia, United States Illinois, United States Iowa, United States Kansas, United States Kentucky, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States Corea, República de España	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas Carboplatin, cisplatin, Docetaxel, Nivolumab, Pemetrexed, TSR-022, TSR-033, TSR-042	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06310564	TitleLow and Intermediate Risk oliGometastatic coloREctal cancEr patieNts Treated With Stereotactic ABlative Radiotherapy	Fase No aplicable	Date Added 2024-03-15	Ubicación Italia	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06300463	TitlePlataforma de estudio de combinaciones de inmunoterapia en metástasis hepáticas de cáncer colorrectal	Fase Fase 2	Date Added 2024-03-08	Ubicación New York, United States	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas AGEN1423, Balstilimab, Botensilimab	Etiquetas MSS/ MMRp
NCT ID NCT06302062	TitlePhase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors	Fase Fase 1	Date Added 2024-03-08	Ubicación China	Prior IO Allowed Sí	CRC-directed No	Status Reclutamiento	Drogas Cyclophosphamide, IL-2, Serplulimab Injection, Tumor Associated Lymph node T cell	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06253520	TitleAutologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer	Fase Fase 1	Date Added 2024-02-12	Ubicación Maryland, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas Aldesleukin, Cyclophosphamide, Fludarabine	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06218914	TitleA Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation	Fase Fase 1	Date Added 2024-01-23	Ubicación California, United States Kansas, United States Missouri, United States New York, United States Pennsylvania, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Activo, no recluta	Drogas	Etiquetas MSI-H/ MMRd, MSS/ MMRp

Showing 21 to 30 of 299 entries